Britain and America have reached a significant bilateral deal that will ensure zero levies on UK medicine exports entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to boost expenditure on drugs through the NHS. This commitment ensures that import taxes on these crucial exports will remain at zero for a duration of 36 months.
This development is in response to previous warnings to hike duties on branded drug products, with potential rates discussed up to 100%.
"This deal between the Britain bolsters the global environment for new treatments and introduces much-needed equity to American-British drug exports," a release said.
Economic Impact
Drugs constitute one of the UK's largest exports to the US, which is clearly the largest destination for large UK drugmakers.
Trade data indicate that in the 12 months prior to September, the UK sold drugs worth £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that span.
"This guarantee secures work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to raise total public funding on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to control costs will be limited at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
The pact comes amid a protracted row between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by assertions that American patients were charged several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the last ten years.
